AbbVie is a research-based biopharmaceutical company. Co.'s portfolio of products includes a line of therapies that addresses serious diseases such as: HUMIRA (adalimumab) to treat autoimmune diseases; oncology products such as IMBRUVICA (ibrutinib) and Venclexta (venetoclax); virology products such as VIEKIRA PAK for the treatment of hepatitis C and Norvir (ritonavir) for the treatment of human immunodeficiency virus-1 infection; metabolic and hormone products that target conditions such as testosterone deficiency; endocrinology products such as Lupron (leuprolide acetate) for the palliative treatment of advanced prostate cancer, treatment of endometriosis and central precocious puberty. We show 24 historical shares outstanding datapoints in our coverage of ABBV's shares outstanding history.
Understanding the changing numbers of ABBV shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like ABBV versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching ABBV by allowing them to research ABBV shares outstanding history
as well as any other stock in our coverage universe. |
Video: Shares Outstanding Importance
